艾昆纬-心灵超越物质：中枢神经系统创新的增长势头（英）

White PaperMind over matter: The growing momentum of CNS innovation How innovators are beating the odds in a high-stakes therapeutic areaMARKUS GORES, Vice President, EMEA Thought Leadership, IQVIASTEFAN LUTZMAYER, Senior Consultant, EMEA Thought Leadership, IQVIATable of contentsIntroduction 1Unmet need is accelerating 1Pushing the frontiers of CNS innovation 3Neuroinflammation 3The gut-brain axis 4Psychedelics 5Digital health 6Innovation momentum and the competitive landscape in CNS 9Deep dive: CNS indication highlights 13I. Alzheimer’s disease 13II. Mental health 15CNS market outlook 19How to succeed as a CNS innovator 20References 22About the authors 26 iqvia.com | 1IntroductionThe global burden of illness related to Central Nervous System (CNS) disorders keeps rising unabatedly, with huge economic implications. By 2030, the global economic cost of mental health conditions alone is projected to reach $6 trillion,1 for example, while the economic burden of Alzheimer’s and related dementias is estimated to rise to $4.7 trillion.2These extraordinary numbers reinforce the urgent need for novel therapeutic interventions to treat CNS disorders, however, the title of our previous publication from 2023, “Two steps forward, one step back: The long road to success in CNS”3 still rings true today, as innovators continue to navigate the high-stakes roller coaster of developing and commercialising new CNS therapies.Notwithstanding well publicised setbacks, numerous examples illustrate the significant progress made in expanding CNS therapeutic options to give hope to patients, their families and caregivers. For example, the approval of Cobenfy represents the first new approach for treating schizophrenia in over 30 years, by targeting cholinergic receptors as opposed to dopamine receptors; NMDA-targeting Spravato (esketamine) for treatment-resistant depression and major depressive disorder with suicidal ideation is well on its way to reach blockbuster status in 2025 and signifies a case in point for the potential of psychedelics as valuable, and commercially viable, CNS therapies; while the approvals of amyloid-targeting therapies Leqembi and Kisunla, and the Lumipulse G test, as the first blood test for diagnosing Alzheimer’s,4 highlight the ongoing, albeit slow, progress in tackling this devastating disease.In this white paper, we will explore the latest trends in CNS innovation, including a deep dive into selected therapeutic breakthroughs, and provide an outlook on the competitive landscape and the CNS market opportunity.Unmet need is acceleratingThe global burden of illness caused by mental health and neurological disorders is significant and continues to rise sharply. For 2021, the WHO5 estimated the combined long-term impact on health-related quality of life of non-communicable mental health and neurological conditions as 304 million disability-adjusted life years (DALYs) globally, an increase of 26% since 2010. For context, this burden consider